🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. Quadrivalent influenza vaccine

    Green Valley (Shanghai) Pharmaceuticals Co.,

    Influenza

    phase 2 mab completed

    1 trial

  2. R348 Ophthalmic Solution, 0.2%

    RIGEL PHARMACEUTICALS INC

    Keratoconjunctivitis Sicca

    phase 2 small molecule completed

    2 trials

  3. R348 Ophthalmic Solution, 0.2%

    RIGEL PHARMACEUTICALS INC

    Chronic Graft-versus-host Disease

    phase 2 small molecule completed

    1 trial

  4. R788

    RIGEL PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  5. R7999 matching placebo, REGN7999

    Lacuna Pharma Pty Ltd

    Non-transfusion dependent beta-thalassemia (NTDT), Beta-thalassemia Resultant Iron overload (IOL)

    phase 2 small molecule active

    1 trial

  6. R906289 Monosodium (R289 Na)

    RIGEL PHARMACEUTICALS INC

    Low Risk Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  7. R926112

    RIGEL PHARMACEUTICALS INC

    Rhinitis, Allergic, Seasonal

    phase 2 small molecule completed

    1 trial

  8. R932333

    RIGEL PHARMACEUTICALS INC

    Lupus Erythematosus, Discoid

    phase 2 small molecule completed

    1 trial

  9. RBD3000 Placebo Injection is a clear, colorless sterile solution for subcutaneous injection, which is formulated by 25 mM phosphate buffer

    Lacuna Pharma Pty Ltd

    Mixed Dyslipidemia

    phase 2 small molecule active

    1 trial

  10. RBD4059 injection, Trombyl 75 mg tabletter, The corresponding placebo consist of the 25 mM phosphate buffer solution with 2 µg of vitamin b2 added for colouring purposes only

    Lacuna Pharma Pty Ltd

    Stable Coronary Artery Disease

    phase 2 small molecule active

    1 trial

  11. REC-1245

    RECURSION PHARMACEUTICALS, INC.

    Unresectable

    phase 2 small molecule active

    1 trial

  12. REC-3964

    RECURSION PHARMACEUTICALS, INC.

    Recurrent Clostridioides Difficile Infection

    phase 2 small molecule terminated

    1 trial

  13. REC-4881

    RECURSION PHARMACEUTICALS, INC.

    AXIN1 Gene Mutation

    phase 2 small molecule terminated

    1 trial

  14. REC-4881

    RECURSION PHARMACEUTICALS, INC.

    Familial Adenomatous Polyposis

    phase 2 small molecule active

    1 trial

  15. REC-994

    RECURSION PHARMACEUTICALS, INC.

    Cerebral Cavernous Malformation

    phase 2 small molecule completed

    1 trial

  16. REGN13335, Placebo to REGN13335, REGN13335

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension (PAH)

    phase 2 small molecule active

    1 trial

  17. REGN7544, REGN7544 Matching Placebo

    Lacuna Pharma Pty Ltd

    Sepsis-Induced Hypotension

    phase 2 small molecule active

    1 trial

  18. REKOVELLE 72 micrograms/2.16 mL solution for injection in a pre-filled pen, Pre-filled pen containing 2.16mL solution, subcutaneous injection

    Ferring Pharmaceuticals

    Idiopathic male infertility (including oligoasthenozoospermia).

    phase 2 small molecule active

    1 trial

  19. RILPIVIRINE , JNJ-16150108

    Xian-Janssen Pharmaceutical

    HIV-1 Infection

    phase 2 small molecule active

    1 trial

  20. RITUXIMAB, MYCOPHENOLATE MOFETIL, YTB323, FLUDARABINE PHOSPHATE, VOCLOSPORIN, TACROLIMUS, RITUXIMAB, MYCOPHENOLIC ACID, CYCLOPHOSPHAMIDE, TOCILIZUMAB, CYCLOPHOSPHAMIDE, AZATHIOPRINE, BELIMUMAB

    Novartis Pharmaceuticals

    Active, refractory systemic lupus erythematosus (SLE), and active, refractory lupus nephritis (LN)

    phase 2 small molecule active

    1 trial

  21. RO7204239, GYM329 Placebo

    Hoffmann-La Roche

    Facioscapulohumeral muscular dystrophy (FSHD)

    phase 2 small molecule active

    1 trial

  22. RO7204239, RO7204239 Placebo, Mounjaro 12.5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 15 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 2.5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 7.5 mg/dose KwikPen solution for injection in pre-f

    Hoffmann-La Roche

    Obesity

    phase 2 small molecule active

    1 trial

  23. RO7234292, RO7234292 Placebo

    Hoffmann-La Roche

    Prodromal and Early Manifest Huntington’s Disease

    phase 2 small molecule active

    1 trial

  24. RO7268489, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, RO7268489 Placebo, RO7268489, RO7268489, RO7268489

    Hoffmann-La Roche

    Progressive Forms of Multiple Sclerosis (PMS)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources